Nancy E. Dempze’s Novo Nordisk NVO Stock Holding History

Nancy E. Dempze’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-14,678	Closed	-$1.01M	–	92
2025 Q2	$1.01M	Buy	14,678 +5,743	+64%	+$391K	0.58%	44
2025 Q1	$620K	Buy	+8,935	New	+$738K	0.37%	53

Other funds holding NVO

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Nancy E. Dempze's NVO Position: Q3 2025 in Review

Nancy E. Dempze sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 14,678 shares — an estimated $1.01M sold.

Nancy E. Dempze first reported a position in NVO in Q1 2025 and held it in 2 quarters. The position peaked at $1.01M in Q2 2025. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

Nancy E. Dempze reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
Nancy E. Dempze sold 14,678 Novo Nordisk shares in Q3 2025, an estimated $1.01M.
Nancy E. Dempze first reported a position in Novo Nordisk in Q1 2025 and held it in 2 quarters.
Nancy E. Dempze's Novo Nordisk position peaked at $1.01M in Q2 2025.
1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Nancy E. Dempze's 13F filing for Q3 2025, filed 10 Nov 2025.